Somatostatin and Neuropeptide Y in Cerebrospinal Fluid: Correlations With Amyloid Peptides Aβ1–42 and Tau Proteins in Elderly Patients With Mild Cognitive Impairment

Emmanuelle Duron (1) , Jean-Sébastien Vidal (2) , Dominique Grousselle , Audrey Gabelle (3, 4) , Sylvain Lehmann (3) , Florence Pasquier (5) , Stéphanie Bombois (6) , Luc Buée (7) , Bernadette Allinquant (8) , Susanna Schraen-Maschke (7) , Christiane Baret , Anne-Sophie Rigaud (9, 10, 11) , Olivier Hanon (11) , Jacques Epelbaum (12)

1 Gériatrie générale et aigüe [Paris]
2 CHU Saint-Antoine [AP-HP]
3 Cellules Souches, Plasticité Cellulaire, Médecine Régénératrice et Immunothérapies (IRMB)
4 CHRU Montpellier - Centre Hospitalier Régional Universitaire [Montpellier]
5 CHRU Lille - Centre Hospitalier Régional Universitaire [CHU Lille]
6 TCDV - Troubles cognitifs dégénératifs et vasculaires - U 1171 - EA 1046
7 JPArc - Centre de Recherche Jean-Pierre AUBERT Neurosciences et Cancer - U837
8 U894 - Centre de Psychiatrie et Neurosciences
9 EA 4468 - Maladie d'Alzheimer : marqueurs génétiques et vasculaires, neuropsychologies
10 UPD5 - Université Paris Descartes - Paris 5
11 Groupe hospitalier Broca
12 MECADEV - Mécanismes Adaptatifs et Evolution

A combination of low cerebrospinal fluid (CSF) Amyloid β1–42 (Aβ1–42) and high Total-Tau (T-Tau) and Phosphorylated-Tau (P-Tau) occurs at a prodromal stage of Alzheimer’s disease (AD) and recent findings suggest that network abnormalities and interneurons dysfunction contribute to cognitive deficits. Somatostatin (SOM) and Neuropeptide Y (NPY) are two neuropeptides which are expressed in GABAergic interneurons with different fates in AD the former only being markedly affected. The aim of this study was to analyze CSF SOM, NPY and CSF Aβ1–42; T-Tau, P-Tau relationships in 43 elderly mild cognitively impairment (MCI) participants from the Biomarker of AmyLoïd pepTide and AlZheimer’s disease Risk (BALTAZAR) cohort. In these samples, CSF SOM and CSF Aβ1–42 on the one hand, and CSF NPY and CSF T-Tau and P-Tau on the other hand are positively correlated. CSF SOM and NPY concentrations should be further investigated to determine if they can stand for early AD biomarkers.Clinical Trial Registration: www.ClinicalTrials.gov, identifier #NCT01315639.

Mots clés: tau proteins; peptides Aβ1–42; neuropeptide Y; somatostatin; cerebrospinal fluid; mild cognitive impairment

Domaines: Neurobiologie

Emmanuelle Duron, Jean-Sébastien Vidal, Dominique Grousselle, Audrey Gabelle, Sylvain Lehmann, et al.. Somatostatin and Neuropeptide Y in Cerebrospinal Fluid: Correlations With Amyloid Peptides Aβ1–42 and Tau Proteins in Elderly Patients With Mild Cognitive Impairment. Frontiers in Aging Neuroscience, 2018, 10, pp.297. ⟨10.3389/fnagi.2018.00297⟩. ⟨hal-02313963⟩